Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

-- At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo --


-- 62% of patients treated with TEPEZZA had... | April 10, 2023

Related Keywords

United States ,Elizabethhz Thompson ,Los Angeles ,Raymond Douglas ,Linkedin ,Nasdaq ,European Group On Grave ,Facebook ,Visa ,Exchange Commission ,Twitter ,Instagram ,Thyroid Eye Disease Program ,Drug Administration ,European Group On Grave Orbitopathy ,Sinai Medical Center ,Horizon Therapeutics ,United Statesfood ,Thyroid Eye Disease ,Primary Endpoint ,Responder Rate ,Key Secondary Endpoint ,Cedars Sinai Medical Center ,Thyroid Eye ,Inflammatory Bowel Disease ,Full Prescribing Information ,United States Securities ,Thyroid Associated ,Grave Disease Is Mediated Through ,Insulin Like Growth Factor ,European Group ,Grave Orbitopathy ,Horizon Therapeutics Public Limited Company Stock Exchange ,News ,Information ,Press Release ,It ,Eek ,Patients ,Reated ,Ith ,Tepezza ,Chieved ,M ,Reduction ,N ,Proptosis ,Rom ,Baseline ,Ompared ,Or ,Whose ,Receiving ,Placebo ,F ,Epezza Hznp Ie00bqpvqz61 ,